MAaGI Medical Unveils i-Series Platform for Multimodal Tumor Therapy

The i-Series platform represents a shift from empirical, experience-based procedures toward data-driven, personalized medicine. By creating digital tumor models for each patient, the system simulates energy field distribution and adjusts thermal dosages in real time based on tumor density and impedance. This precision allows clinicians to target lesions while simultaneously stimulating an in-situ immune response, effectively acting as a localized vaccine.

Clinical data supporting this approach appeared recently in the journal Theranostics, highlighting the identification of CX3CR1⁺GPR56⁺ CD8⁺ T cells as key mediators of long-term antitumor immunity. Furthermore, research presented at the 2026 American Society of Clinical Oncology meeting indicated that combining this multimodal therapy with immunotherapy extended overall survival in pancreatic cancer patients by eight months compared to conventional chemotherapy. The technology is currently deployed across more than ten Chinese hospitals, with international experts from the UK, France, and Japan recognizing its potential to reduce recurrence and metastasis risks in complex oncology cases.